Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
1.070
+0.020 (1.90%)
At close: May 12, 2025, 4:00 PM
1.050
-0.020 (-1.87%)
After-hours: May 12, 2025, 6:04 PM EDT

Virax Biolabs Group Revenue

Virax Biolabs Group had revenue of $4.95K in the half year ending September 30, 2024, a decrease of -14.01%. This brings the company's revenue in the last twelve months to $84.87K, up 7.03% year-over-year. In the fiscal year ending March 31, 2024, Virax Biolabs Group had annual revenue of $156.42K with 1,727.11% growth.

Revenue (ttm)
$84.87K
Revenue Growth
+7.03%
P/S Ratio
33.04
Revenue / Employee
$4,992
Employees
17
Market Cap
4.65M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Mar 31, 2024156.42K147.86K1,727.11%
Mar 31, 20238.56K--
Mar 31, 2022---
Mar 31, 2021123.82K23.94K23.97%
Mar 31, 202099.88K--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 410.06B
Johnson & Johnson 89.33B
Merck & Co. 63.92B
AbbVie 57.37B
AstraZeneca 54.98B
Novartis AG 53.22B
Eli Lilly and Company 49.00B
Novo Nordisk 43.92B
Revenue Rankings